DeTIL-0255

N/A

Report date: 2024/05/04 20:00:04

Base Information

Drug NameDeTIL-0255

Drug Alias NameDeTIL-0255NX-0255NX-DeTIL-0255-201

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionT lymphocyte replacementsE3 ubiquitin-protein ligase CBL-B inhibitors

TargetsE3 ubiquitin-protein ligase CBL-B

Therapy Area/IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNurix Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNurix Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsOvarian Neoplasms

Other Information

ATC CodeN/A